INTRODUCTION
Parainfluenza virus type 3 (PIV-3), the most commonly detected type of PIV, occasionally causes outbreaks among hematopoietic cell transplantation (HCT) recipients. [1] [2] [3] [4] [5] [6] Approximately 30-40% of recipients who experience PIV-3 upper respiratory tract infection (URI) progress to lower respiratory tract disease (LRD), often associated with high mortality. [7] [8] [9] [10] [11] [12] [13] Historically, risk factors for PIV LRD include lymphopenia, high-dose corticosteroid use, myeloablative conditioning, infection early after HCT and respiratory co-pathogens. [9] [10] [11] 14, 15 Humoral immunity is known to be important for prevention of severe respiratory viral infections. Although several studies have shown that normalization of IgG level may require up to 1 year after HCT, 16, 17 little is known about Ab production after HCT, especially Ag-specific Abs. With respect to virus-specific Ab titers and outcome, some studies of respiratory syncytial virus (RSV) infection have demonstrated that high serum Ab titers correlate with protection from RSV infection and progression to severe disease in community-acquired infection. [18] [19] [20] [21] [22] However, limited data exist regarding the role of Ab titer and PIV infection in HCT recipients.
Evidence from studies in non-transplant populations suggests that humoral immunity may act to modify the severity of PIV infection. Infants born with high titers of maternal neutralizing Ab to PIV-3 are generally protected against primary infection during the first months of life. 23 Studies in children have shown that the risk of re-infection, severity of respiratory illness and duration of virus shedding are inversely related to levels of circulating serum Ab before infection. 24, 25 Although some heterologous Ab to PIV serogroups may occur with acute infection, 26 protection is typically type-specific. 27 Thus, it is reasonable to hypothesize that a protective effect may occur from PIV-3 type-specific Ab in HCT recipients.
Our objectives were to identify factors influencing the levels of PIV-3-specific hemagglutination inhibition (HAI) Abs following HCT, and to examine associations between PIV-3-specific Ab titer and outcomes of PIV-3 infection among HCT recipients with post-transplantation PIV-3 infection.
PATIENTS AND METHODS

Study design
We retrospectively evaluated 172 patients who had a first episode of PIV-3 infection following allogeneic HCT at Fred Hutchinson Cancer Research Center (FHCRC) between 1992 and 2009 and an available serum sample at the time of PIV-3 infection. We also collected information regarding demographic and transplant characteristics for all other allogeneic HCT recipients with PIV-3 infection during the same time period. PIV-3 infection was defined as PIV-3 detection in any respiratory sample by viral culture, direct fluorescent Ab test and/or PCR. The Institutional Review Board at FHCRC approved the study. PIV-3 Ab in HCT recipients S Seo et al maxillary sinus (n = 3) or sputum (n = 3) in patients with signs and/or symptoms of URI. PIV-3 LRD was defined as PIV-3 detection in bronchoalveolar lavage (n = 41), lung biopsy (n = 3) or autopsy (n = 2) samples in patients with lower respiratory tract symptoms and/or new pulmonary infiltrates. It is standard practice at FHCRC for bronchoscopy to be performed, if feasible, in patients with any lower respiratory tract symptoms or radiographic findings of LRD. Progression from URI to LRD was defined among patients who initially presented with URI as subsequent development of LRD. Underlying disease risk groups at transplantation were classified as either standard or high risk based on a previous report. 28 Myeloablative conditioning regimens consisted mainly of high-dose CY and BU or fractionated TBI (⩾12 Gy). Reduced intensity conditioning regimens consisted mainly of fludarabine with a single fraction of TBI (2 Gy). A co-pathogen was defined as a pathogenic bacteria, fungus or opportunistic virus detected with PCR, culture or direct staining methods obtained from concomitant upper or lower respiratory samples. Two patients were excluded because one received high-dose i.v. Ig and another received a blinded study drug before PIV infection.
f To maintain levels of 4400 mg/dL, as needed.
g n = 41 subjects with both pre-HCT recipient and donor titer available, thus donor titer not included in full multivariable model. In adjusted analyses for this smaller group, donor titer was not significantly associated with the outcome.
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Laboratory methods
We tested PIV-3 Ab titers in sera stored in a repository containing prospectively collected specimens. Sera tested in this study consisted of pre-transplantation sera from donor and transplant recipient pairs, as well as sera obtained from recipients within 3 weeks before diagnosis of PIV-3 infection (URI and/or LRD). PIV-3 Ab titers were measured using HAI assay, using viral HA derived from the PIV-3 Washington/57 strain. 29, 30 Statistical analysis
We compared patient characteristics across the following groups: patients with URI alone, progression to LRD and LRD alone, as well as between the study cohort with serum tested by HAI and the allogeneic HCT recipients with PIV-3 infection during the same time period who were not in the study. We used Fisher's exact or χ 2 tests for categorical variables, and Wilcoxon rank sum or Kruskal-Wallis tests for continuous variables, as appropriate. Linear regression was used to identify factors influencing the mean HAI titers after HCT. Variables with P ⩽ 0.1 in univariable models were included in the multivariable model. The correlation between recipient and donor Ab titers before HCT was evaluated using Pearson's correlation coefficient. The probability of LRD was estimated by cumulative incidence curves from the time of HCT, treating death as a competing risk. The logrank test was used to compare hazards of time-to-event outcomes between high and low pre-HCT Ab titers. Cross-sectional associations between risk factors present before infection with occurrence of LRD were evaluated using logistic regression models. A multivariable logistic regression model was created with pre-HCT recipient titer included a priori and variables with P ⩽ 0.1 in univariable models added in a stepwise manner to identify confounders for inclusion in the final model, keeping factors that modified the effect of pre-HCT titer by 410% and limiting to four covariates because of numbers of events. Among subjects with an URI, factors associated with progression from URI to LRD were evaluated using Cox proportional hazards models using time from URI. Recipient titer at diagnosis was included in the multivariable model a priori, and variables with P ⩽ 0.1 in univariable models were evaluated in bivariable models to determine relevant confounding factors. Two-sided P-values o0.05 were considered statistically significant. Analyses were performed using SAS 9.3 (SAS Institute, Inc., Cary, NC, USA).
RESULTS
Patient characteristics
Among the 172 patients with PIV-3 infection and available serum for HAI testing, 126 (73%) had URI alone, 20 (12%) progressed from URI to LRD and 26 (15%) had LRD without detection of prior URI. Serum samples were collected at a median of 4 days (range, 0-21 days) before diagnosis of PIV-3 infection. Patient characteristics are outlined in Table 1 . The median age at HCT was 41.1 years (range, 1-73 years). The median time between HCT and PIV-3 infection was 68.5 days (range, 3-1678 days) and all but four were diagnosed within 1 year after transplantation. The patients with URI alone were more frequently transplanted from a related donor and had a higher lymphocyte count at diagnosis of PIV-3 infection ( Table 1 ). The median Ab titers are shown in Table 1 .
In the same time period (1992-2009), 178 allogeneic HCT recipients had PIV-3 infections without serum testing. The comparison between 172 patients in the cohort with Ab testing and the patients without Ab testing showed that patients in the Ab cohort were older (41 years (range, 1-73) vs 37 years (range, 0-74), P = 0.011), more likely to receive related donor transplants (60% vs 43%, P = 0.001) and had PIV-3 infection earlier after HCT (69 days (range, 3-1678) vs 78 days (range, 1-3140), P = 0.002; Supplementary Table) .
Factors influencing post-transplantation Ab titers HAI serum Ab titers against PIV-3 before HCT were measured in 166 of the 172 patients, whereas serum was tested from only 47 donors. Sera from all the 172 patients were measured before PIV-3 infection. In a multivariable model, higher pre-HCT recipient Ab titer was associated with high Ab titer after HCT (adjusted mean difference 0.38 (95% confidence interval (CI) 0.26, 0.50), P o 0.001; Table 2 ). Although significant in univariable analysis, age at HCT, conditioning regimen and GHVD prophylaxis were not significantly associated with Ab level after HCT in the multivariable model (Table 2 ). In the subset of subjects with both pre-HCT donor and recipient Ab titers available (N = 41), pre-HCT donor Ab titer was evaluated in a separate multivariable model adjusted for age at HCT, conditioning regimen and recipient Ab titer. Pre-HCT donor Ab titer was not significantly associated with recipient Ab level after HCT (adjusted mean difference − 0.04 (95% CI − 0.27, 0.20), P = 0.76); pre-HCT donor Ab is excluded from the multivariable model in Table 2 because of the reduced sample size with donor titer available.
Ab titers in patients with URI and LRD The median Ab titer before HCT and the median donor Ab titer were compared between patients with URI alone and with LRD, and were similar in each group (left two in Figure 1) . Moreover, the median recipient Ab titer before HCT was similar to that of healthy donors. Among 41 donor-recipient serum pairs available, 27 patients had related donors; Ab titers between related donor and recipient pairs had strong correlation (Pearson's correlation coefficient 0.73). The median Ab titers at diagnosis (URI or LRD) were similar (second from the right in Figure 1 ).
To assess for an effect of seasonality on Ab levels, we compared pre-transplantation Ab titers in summer (May to July) and winter (November to January) samples and found no significant differences. (Recipient median titer (Log 2 ) was 6.0 (n = 57) and 6.0 (n = 36) in samples collected in summer and winter, respectively, P = 0.29; donor median titer (Log 2 ) was 7.0 (n = 17) and 7.0 (n = 10) in samples collected in summer and winter, respectively, P = 0.26).
Timing and factors associated with LRD Next, we examined the timing of LRD occurrence during the 3 months after HCT within this population. Patients with pre-HCT Ab titers ⩽ 5 (Log 2 ) (value closest to the lowest quartile with 23% titers is ⩽ 5) had a higher cumulative incidence of LRD than those with pre-HCT Ab titers 45 (P = 0.11 on day 30, P = 0.12 on day 90; Figure 2 ). Donor Ab titers were evaluated comparing titers ⩽ 5 (11th percentile) and 45, and titers of ⩽ 6 (43rd percentile) and 46 and were not associated with the incidence of LRD in either analysis (P = 0.57 on day 30 and P = 0.43 on day 90, and P = 0.64 on day 30 and P = 0.89 on day 90, respectively).
In univariable logistic regression analysis, neither pre-HCT recipient Ab nor donor Ab analyzed as a continuous variable was associated with the presence of LRD (Table 3) . In a multivariable model, pre-HCT recipient Ab titer above 5 (Log 2 ) was not significantly associated with the occurrence of LRD (adjusted OR 0.50 (95% CI 0.21, 1.22), P = 0.13; Table 3 ). Transplant year 1992-2000, lymphocyte count o100 × 10 6 /L at diagnosis and presence of a co-pathogen were all significantly associated with LRD (Table 3 ).
Progression to LRD Among 146 patients with PIV-3 URI, 20 (14%) progressed to LRD with a median progression time of 7 days (range, 1-21 days). The median Ab titers at URI diagnosis were similar between patients with URI alone and in those who progressed from URI to LRD; right in Figure 1) . Moreover, Ab titer before URI was not a significant risk factor for progression from URI to LRD (HR 1.09 (95% CI 0.77, 1.53), P = 0.62). Pre-URI Ab titers did not reach significance after adjusting for any other factors including lymphocyte count at URI diagnosis, transplant year and steroid use at URI diagnosis (data not shown). Probability of LRD Figure 2 . Cumulative incidence of PIV-3 LRD by patient pretransplantation HAI Ab titers above or below 5 (log 2 ) (closest to the lowest quartile; day 30, P = 0.11; day 90, P = 0.12; there were 166 patients at risk by day 30 and 160 patients at risk by day 90). URI: upper respiratory tract infection; LRD: lower respiratory tract disease. 
DISCUSSION
This study suggests that, among subjects who developed PIV-3 infection, titers of PIV type 3-specific HAI Abs after HCT were associated with their pre-HCT recipient Ab titer. The level of PIV-3 recipient Ab titer before HCT was similar to that of donor Ab titer and was not significantly associated with occurrence of LRD after HCT.
Our study showed that pre-HCT recipient Ab titers, but not donor titers, or age, conditioning regimen or GVHD prophylaxis, are associated with post-HCT Ab titer in patients who developed PIV-3 infection after HCT. Only a few reports have indicated recovery time of total serum IgG levels after HCT, which may be 1 year or more. 16, 17 In some patients, recipient-type Igs are detected even years after HCT. 31 Moreover, limited data on the change of Ag-specific Ab after HCT have been reported. As posttransplantation Ab titers were mostly obtained within 1 year after HCT in this study, recipient-derived plasma cells may have an important role in this period.
Our data showed that the pre-transplantation Ab titers in HCT recipients with PIV-3 infection are similar to those in healthy donors. Although most patients had chemotherapy for underlying disease before beginning the transplantation process, Ab titers were not affected. This result suggests that following chemotherapy, patients have a similar risk of acquisition of respiratory viral infections as do immunocompetent persons, although progression to LRD or mortality may occur in HCT recipients with important risk factors, such as severe myelosuppression or co-infections. [8] [9] [10] [11] 14 Ab titers in related donor and recipient pairs showed a strong correlation, suggestive of similar exposure history.
To our knowledge, there are no previous studies that describe the relationship between PIV-3 HAI titers associated with PIV-3 URI and PIV-3 LRD in HCT recipients. Our study suggested that there is no association between patient and donor Abs before HCT and occurrence of LRD among HCT recipients. No association was found between pre-diagnosis Ab titer in patients and progression from URI to LRD. A recent study of outcomes of PIV LRD after HCT did not show an effect of high-dose i.v. Ig on mortality after PIV LRD, 7 although this analysis was limited by sample size and the amount of PIV-specific Ab in these i.v. Ig products is unknown. Although data suggest that serum Ab is protective against PIV acquisition and disease severity in healthy infants and children, 23, 24 mechanisms of protection may differ for HCT patients. Our data did show significant associations with lymphopenia and presence of a co-pathogen at PIV-3 diagnosis, both previously reported as risk factors for PIV LRD.
Some RSV studies suggest that high RSV-specific Ab titer is related to a low incidence of RSV infection and progression from URI to LRD in non-transplant settings, [18] [19] [20] [21] although an analysis in HCT recipients did not find association between pre-and post-transplantation donor and recipient RSV subtype-specific neutralizing Ab levels and LRD progression. 32 Likewise, recent papers have demonstrated an apparent lack of effect of Ig and RSV-specific MoAb (palivizumab) on outcomes among HCT patients with RSV LRD. 28 This study has several limitations. Since the patients in this retrospective observational study were selected based on availability of sera for laboratory testing, certain subsets of our samples were limited in number and some differences were observed in donor type, age and timing of PIV-3 infection after HCT in patients in the PIV-3 Ab cohort compared with other patients transplanted during the study period. The small sample size, especially for donor Ab titer, may have restricted our ability to reach statistical significance in some analyses. Another limitation is that there was no control group of uninfected HCT recipients. As all patients in this cohort had PIV-3 infection, the prospective relationship between pre-transplantation Ab titer and acquisition of PIV-3 infection was not evaluated; rather the results here focus on comparisons of characteristics between groups of infected subjects (URI alone vs LRD or groups defined by titer levels). Finally, the definition of LRD in this study is based on the detection of PIV-3 in the lung. 7 As standard practice at our center includes a low threshold to perform bronchoscopy in patients with lower respiratory tract symptoms or radiographic findings of LRD, we feel that the definition of LRD based on PIV-3 detection in bronchoalveolar lavage is reasonable. However, some bias by attending physicians as to whether bronchoscopy was performed was likely inevitable.
In conclusion, we found that higher pre-transplantation HAI Ab titer against PIV-3 in HCT recipients is associated with higher HAI Ab titers after HCT among PIV-3-infected subjects. Our study did not find significant associations between pre-or posttransplantation HAI titers of Abs against PIV-3 in HCT recipients and the occurrence of, or progression to, PIV-3 LRD after transplantation or URI, respectively. Further prospective studies to evaluate the dynamics of PIV-3-specific Ab responses and the relative contribution of PIV-3-specific Ab (as well as type-specific Ab for other PIV subtypes) to protection from infection acquisition and progression to LRD in HCT recipients are warranted. Given the high morbidity and mortality associated with PIV infection after HCT, and the critical dearth of novel and effective therapies, there is a need for a multi-faceted approach in treating PIV. On the basis of our lack of associations with HAI Ab titers, a focus on antiviral therapeutics and interventions directed at cell-mediated rather than humoral immunity may be the highest priority for therapeutic intervention for PIV infections in HCT recipients.
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